Prevalence, characteristics, and risk factors of occult uterine cancer in presumed benign hysterectomy

Published:March 07, 2019DOI:


      Occult uterine cancer at the time of benign hysterectomy poses unique challenges in patient care. There is large variability and uncertainty in estimated risk of occult uterine cancer in the literature and prior research often did not differentiate/include all subtypes.


      To thoroughly examine the prevalence of occult uterine cancer in a large population-based sample of women undergoing hysterectomy for presumed benign indications and to identify associated risk factors.

      Study Design

      Using the New York Statewide Planning and Research Cooperative System database, we identified 229,536 adult women who underwent an inpatient or outpatient hysterectomy for benign indications during the period October 1, 2003 to December 31, 2013 at civilian hospitals and ambulatory surgery centers throughout the state. Diagnosis of corpus uteri cancer within 28 days after the index hysterectomy was determined using linked state cancer registry data. We estimated the prevalence of occult uterine cancer (overall and by subtype) and developed and validated risk prediction models using a random split sample approach.


      Overall, 0.96% (95% confidence interval: 0.92–1.00%) of the women had occult uterine cancer, including 0.75% (95% confidence interval: 0.71–0.78%) with endometrial carcinoma and 0.22% (95% confidence interval: 0.20–0.23%) with uterine sarcoma. The prevalence of leiomyosarcoma was 0.15% (95% confidence interval: 0.13–0.17%). Seventy-one percent of the endometrial carcinomas and 58.0% of the uterine sarcomas were at localized stage. The risk for occult uterine cancer ranged from 0.10% in women aged 18–29 years to 4.40% in women aged ≥75 years; and varied from 0.14% in women undergoing hysterectomy for endometriosis to 0.62% for uterine fibroids and 8.43% for postmenopausal bleeding. The risk of occult uterine cancer was also significantly associated with race/ethnicity, obesity, comorbidity, and personal history of malignancy. Prediction models incorporating these risk factors had high negative predictive values (99.8% for endometrial carcinoma and 99.9% for uterine sarcoma) and good rule-out accuracy despite low positive predictive value.


      In women undergoing hysterectomy for presumed benign indications, 0.96% had unexpected uterine cancer. Patient characteristics such as age, surgical indication, and medical history may help guide risk stratification.

      Key words

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to American Journal of Obstetrics & Gynecology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Tsui C.
        • Klein R.
        • Garabrant M.
        Minimally invasive surgery: national trends in adoption and future directions for hospital strategy.
        Surg Endosc. 2013; 27: 2253-2257
      1. Practice Bulletin No. 149: Endometrial cancer.
        Obstet Gynecol. 2015; 125: 1006-1026
      2. U.S. Food and Drug Administration. FDA updated assessment of the use of laparoscopic power morcellators to treat uterine fibroids. December 2017. Silver Spring, MD. Available at: Accessed August 14, 2018.

        • Hartmann K.E.
        • Fonnesbeck C.
        • Surawicz T.
        • et al.
        Management of uterine fibroids. Comparative Effectiveness Review No. 195. (Prepared by the Vanderbilt Evidence-based Practice Center under Contract No. 290-2015-00003-I.) AHRQ Publication No. 17(18)-EHC028-EF.
        Agency for Healthcare Research and Quality, Rockville, MDDecember 2017 (Available at:)
        • Andy U.U.
        • Nosti P.A.
        • Kane S.
        • et al.
        Incidence of unanticipated uterine pathology at the time of minimally invasive abdominal sacrocolpopexy.
        J Minim Invasive Gynecol. 2014; 21: 97-100
        • Balgobin S.
        • Maldonado P.A.
        • Chin K.
        • Schaffer J.I.
        • Hamid C.A.
        Safety of manual morcellation after vaginal or laparoscopic-assisted vaginal hysterectomy.
        J Minim Invasive Gynecol. 2016; 23: 542-547
        • Ehdaivand S.
        • Simon R.A.
        • Sung C.J.
        • Steinhoff M.M.
        • Lawrence W.D.
        • Quddus M.R.
        Incidental gynecologic neoplasms in morcellated uterine specimens: a case series with follow-up.
        Hum Pathol. 2014; 45: 2311-2317
        • Hill A.J.
        • Carroll A.W.
        • Matthews C.A.
        Unanticipated uterine pathologic finding after morcellation during robotic-assisted supracervical hysterectomy and cervicosacropexy for uterine prolapse.
        Female Pelvic Med Reconstr Surg. 2014; 20: 113-115
        • Rodriguez A.M.
        • Asoglu M.R.
        • Sak M.E.
        • Tan A.
        • Borahay M.A.
        • Kilic G.S.
        Incidence of occult leiomyosarcoma in presumed morcellation cases: a database study.
        Eur J Obstet Gynecol Reprod Biol. 2016; 197: 31-35
        • Wright J.D.
        • Tergas A.I.
        • Burke W.M.
        • et al.
        Uterine pathology in women undergoing minimally invasive hysterectomy using morcellation.
        JAMA. 2014; 312: 1253-1255
        • Kosary C.L.
        Cancer of the corpus uteri.
        in: Ries L.A.G. Young J.L. Keel G.E. Eisner M.P. Lin Y.D. Horner M.-J. SEER Survival Monograph: Cancer Survival Among Adults: U.S. SEER Program, 1988-2001, Patient and Tumor Characteristics. National Cancer Institute SEER Program, Bethesda, MD2007 (NIH Pub. No. 07-6215. Available at:)
        • New York State Department of Health
        Statewide Planning and Research Cooperative System (SPARCS).
        (Available at:)
        Date accessed: August 14, 2018
        • New York State Department of Health
        NYS Cancer Registry and Cancer Statistics.
        (Available at:)
        • National Cancer Institute
        Surveillance, Epidemiology, and End Results (SEER) Program. Site Recode ICD-O-3/WHO 2008 Definition.
        (Available at:)
        • Boll D.
        • Verhoeven R.H.
        • van der Aa M.A.
        • et al.
        Incidence and survival trends of uncommon corpus uteri malignancies in the Netherlands, 1989-2008.
        Int J Gynecol Cancer. 2012; 22: 599-606
      3. American Joint Committee on Cancer. Collaborative Stage Data Collection System. Schema Version 02.05. Chicago, IL. Available at: Accessed August 5, 2018.

        • Baldwin L.M.
        • Klabunde C.N.
        • Green P.
        • Barlow W.
        • Wright G.
        In search of the perfect comorbidity measure for use with administrative claims data: does it exist?.
        Med Care. 2006; 44: 745-753
        • Elixhauser A.
        • Steiner C.
        • Harris D.R.
        • Coffey R.M.
        Comorbidity measures for use with administrative data.
        Med Care. 1998; 36: 8-27
        • Zou G.
        A modified poisson regression approach to prospective studies with binary data.
        Am J Epidemiol. 2004; 159: 702-706
        • Perkins N.J.
        • Schisterman E.F.
        The inconsistency of “optimal” cutpoints obtained using two criteria based on the receiver operating characteristic curve.
        Am J Epidemiol. 2006; 163: 670-675
        • Mitchell A.J.
        Sensitivity x PPV is a recognized test called the clinical utility index (CUI+).
        Eur J Epidemiol. 2011; 26: 251-252
      4. U.S. Food and Drug Administration. Quantitative assessment of the prevalence of unsuspected uterine sarcoma in women undergoing treatment of uterine fibroids: summary and key findings. April 17, 2014. Silver Spring, MD. Available at: Accessed August 26, 2018.

        • Perkins R.B.
        • Handal-Orefice R.
        • Hanchate A.D.
        • Lin M.
        • Paasche-Orlow M.K.
        Risk of undetected cancer at the time of laparoscopic supracervical hysterectomy and laparoscopic myomectomy: implications for the use of power morcellation.
        Womens Health Issues. 2016; 26: 21-26
        • Desai V.B.
        • Wright J.D.
        • Schwartz P.E.
        • et al.
        Occult gynecologic cancer in women undergoing hysterectomy or myomectomy for benign indications.
        Obstet Gynecol. 2018; 131: 642-651
        • Chalas E.
        • Clarke-Pearson D.
        • Berek J.S.
        Letter: Occult gynecologic cancer in women undergoing hysterectomy or myomectomy for benign indications.
        Obstet Gynecol. 2018; 132: 519
        • Dijkhuizen F.P.
        • Mol B.W.
        • Brolmann H.A.
        • Heintz A.P.
        The accuracy of endometrial sampling in the diagnosis of patients with endometrial carcinoma and hyperplasia: a meta-analysis.
        Cancer. 2000; 89: 1765-1772
        • Mahnert N.
        • Morgan D.
        • Campbell D.
        • Johnston C.
        • As-Sanie S.
        Unexpected gynecologic malignancy diagnosed after hysterectomy performed for benign indications.
        Obstet Gynecol. 2015; 125: 397-405
        • Pritts E.A.
        • Vanness D.J.
        • Berek J.S.
        • et al.
        The prevalence of occult leiomyosarcoma at surgery for presumed uterine fibroids: a meta-analysis.
        Gynecol Surg. 2015; 12: 165-177
        • Cooper G.S.
        • Yuan Z.
        • Stange K.C.
        • Dennis L.K.
        • Amini S.B.
        • Rimm A.A.
        The sensitivity of Medicare claims data for case ascertainment of six common cancers.
        Med Care. 1999; 37: 436-444
        • Sakshaug J.W.
        • Weir D.R.
        • Nicholas L.H.
        Identifying diabetics in Medicare claims and survey data: implications for health services research.
        BMC Health Serv Res. 2014; 14: 150